Torcetrapib and atorvastatin--should marketing drive the research agenda?
Avorn
Jerry
J
Harvard Medical School, Boston, USA.
D000924:Anticholesteremic Agents / Q000737:chemistry / Q000627:therapeutic use; D000069059:Atorvastatin; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL / Q000097:blood; D002986:Clinical Trials as Topic / Q000191:economics / Q000592:standards; D003324:Coronary Artery Disease / Q000188:drug therapy*; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry / Q000191:economics; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006538:Heptanoic Acids / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D040541:Marketing; D015394:Molecular Structure; D011758:Pyrroles / Q000737:chemistry / Q000627:therapeutic use*; D011804:Quinolines / Q000737:chemistry / Q000627:therapeutic use*; D012107:Research Design; D014481:United States; D014486:United States Food and Drug Administration
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D004338:Drug Combinations; D006023:Glycoproteins; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D011804:Quinolines; C483909:torcetrapib; D000069059:Atorvastatin